الفهرس 
Cover EnglishOnly 14 pages are availabe for public view
 |  | from | 160 |  |  |
| | | from | 160 | | |
Abstract
Background: Multiple sclerosis is an Inflammatory and neurodegenerative disease of the central nervous system of unknown reason or definite cure. Purpose: Proposing safe alternative therapies for the early management of multiple sclerosis. Study Design: Repeated measures randomized control trial. Materials and methods: 24 patients with relapsing-remitting multiple Sclerosis, from both sexes completed the study, age 25-45 years; randomly assigned into four groups. Seven patients in the control group (1); received monthly IV infusion of (1g) Solu-Medrol therapy for multiple sclerosis. Six Patients in group (2) received Solu-Medrol plus low intensity laser therapy LILT 850 nm. Six patients in group (3) received Solu-Medrol plus broad band ultraviolet B radiation BB-UVBR (280-320 nm). Five patients in group (4) received Solu-Medrol, scanner LILT and BB-UVBR; all three groups received sessions 3 days/week for 12 sessions. Expanded disability status Scale (EDSS), Fatigue severity scale (FSS), visual evoked potential (VEP), Hreflex latency, and H/M Ratio were assessed pre-treatment, post treatment, 3 months follow up. Results: Statistically significant reduction of fatigue severity FSS was recorded between the four groups post treatment (p=.013) in favor of group (4) and highly significant one (p=.005) at follow up in favor of the group (3). Conclusion: BB-UVBR therapy solely has the potential to efficiently ameliorate fatigue, disability status, and Optic neuritis rather than LILT, while LILT is more efficient in reducing spasticity. With a possible undermining effect of combining LILT to UVBR therapy.